Inhaled Mometasone Increases Disease Severity Markers in Sickle Cell Disease
A 48-week clinical trial of adults with sickle cell disease and episodic respiratory symptoms found that daily use of inhaled mometasone increased soluble VCAM-1, a marker of disease severity, by … Read More